AnalytiCon Discovery To Identify New Natural Compounds For Johnson & Johnson Pharmaceutical Research & Development
According to the agreement, AnalytiCon will apply its proprietary MEGAbolite® technology to isolate and characterize small molecule compounds from a variety of biosources to find novel and pharmaceutically active compounds on behalf of J&JPRD. AnalytiCon will profile both its own extensive proprietary biological collections and biomaterials provided by Tibotec Pharmaceuticals Ltd. (Tibotec) that are described in ethnobotany for active compounds. In addition, AnalytiCon will carry out all tasks beginning with the acquisition of plant and microbial material, and the isolation and fractionation of the contained natural product compounds up to their analytical characterization. AnalytiCon expects to deliver more than 500 highly purified compounds with fully elucidated structures to J&JPRD and Tibotec for drug discovery screening activities. AnalytiCon also expects to establish the resupply protocol in order to guarantee compound supply for J&JPRD's followup discovery work on an as-needed basis.
"We have had a long business relationship with J&JRPD and we are excited to continue this relationship," said Dr. Lutz Müller-Kuhrt, CEO of AnalytiCon Discovery GmbH. "We expect to supply a number of novel compounds and we look forward to working with J&JPRD within their discovery process."
The internationally operating AnalytiCon Discovery GmbH is a worldwide market-leader in the field of structurally fully elucidated natural product libraries. On the basis of its ready-to-screen technology in the field of natural products (MEGAbolite®) and natural product analogues (NatDiverseTM) the company enjoys an exceptional market positioning. AnalytiCon has direct access to roughly a quarter of all known natural compounds worldwide, i.e. in their pure and structurally fully elucidated form. The company is able to offer its clients a complete Supply-Chain-Management from the initial biomaterial to the final lead compound.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.